home / stock / nxtc / nxtc quote
Last: | $ |
---|---|
Change Percent: | -2.82% |
Open: | $46.69 |
Close: | $45.15 |
High: | $46.81 |
Low: | $44.70 |
Volume: | 147,436 |
Last Trade Date Time: | 02/12/2020 04:42:13 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $46.69 | $45.15 | $46.81 | $44.70 | 147,436 | 02-12-2020 |
$ | $44.67 | $46.46 | $46.92 | $43.87 | 198,896 | 02-11-2020 |
$ | $45.08 | $44.47 | $46.275 | $43.54 | 275,271 | 02-10-2020 |
$ | $44.72 | $45.23 | $45.65 | $44.39 | 272,966 | 02-07-2020 |
$ | $45.44 | $44.72 | $46.01 | $43.49 | 330,752 | 02-06-2020 |
$ | $46.17 | $45.20 | $47.21 | $44.7551 | 268,332 | 02-05-2020 |
$ | $44.07 | $45.78 | $46.09 | $42.8282 | 330,442 | 02-04-2020 |
$ | $42.93 | $43.54 | $44.00 | $42.10 | 212,538 | 02-03-2020 |
$ | $43.18 | $42.75 | $44.00 | $42.30 | 98,490 | 01-31-2020 |
$ | $42.77 | $43.50 | $43.695 | $42.00 | 273,939 | 01-30-2020 |
$ | $43.24 | $43.25 | $44.00 | $42.50 | 185,533 | 01-29-2020 |
$ | $44.94 | $43.28 | $45.63 | $42.19 | 192,565 | 01-28-2020 |
$ | $43.33 | $44.60 | $45.32 | $42.50 | 139,272 | 01-27-2020 |
$ | $47.15 | $44.51 | $47.80 | $42.56 | 284,051 | 01-24-2020 |
$ | $47.41 | $47.10 | $47.61 | $44.77 | 385,363 | 01-23-2020 |
$ | $49.96 | $47.66 | $50.32 | $47.25 | 231,136 | 01-22-2020 |
$ | $49.97 | $49.88 | $51.33 | $49.00 | 244,326 | 01-21-2020 |
$ | $53.32 | $50.12 | $53.70 | $49.90 | 231,263 | 01-20-2020 |
$ | $53.32 | $50.12 | $53.70 | $49.90 | 230,525 | 01-17-2020 |
$ | $51.62 | $52.90 | $54.95 | $50.98 | 211,395 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
NextCure Inc. Company Name:
NXTC Stock Symbol:
NYSE Market:
BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S. Chr...
BELTSVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of new preclinical data on ...
BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discov...